First NOAC reversal agent Praxbind lands in multiple univ. hospitals

The Boehringer Ingelheim’s first reversal agent for novel oral anticoagulants(NOAC), ‘Praxbind(idarucizumab),’ is promptly landing in large university hospitals after its launch.

After the launch last June, Praxbind first became available for prescription as passing the 134^th Drug Committee of Asan Medical Center on June.

In this month, moreover, Praxbind is looking forward to new registratio...